Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus

NCT02229383 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

464

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus

Interventions

DRUG: Exenatide
DRUG: Exenatide matching placebo

Sponsor

AstraZeneca